Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D04CTD
|
|||
Drug Name |
SNDX-6352
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
Company |
Syndax Pharmaceuticals Waltham, MA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Macrophage colony-stimulating factor 1 receptor (CSF1R) | Target Info | Antagonist | [1] |
KEGG Pathway | MAPK signaling pathway | |||
Ras signaling pathway | ||||
Rap1 signaling pathway | ||||
Cytokine-cytokine receptor interaction | ||||
Viral protein interaction with cytokine and cytokine receptor | ||||
PI3K-Akt signaling pathway | ||||
Osteoclast differentiation | ||||
Hematopoietic cell lineage | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Acute myeloid leukemia |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.